The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2- Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered [0.03%]
当考虑非药品费用时美国治疗HR阳性/HER2阴性转移性乳腺癌患者的CDK4/6抑制剂药物经济学：当考虑非药品费用时
Asal Pilehvari,Wen You,Gretchen Kimmick et al.
Asal Pilehvari et al.
Background and objective: Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy (ET) significantly enhance progression-free survival and overall survival in patients diagnosed with HR+/HER2- me...
Authors' Reply to Noguchi et al. Comment on: "Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors Used in Patients with Diabetes and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database" [0.03%]
回复评论：钠-葡萄糖协同转运蛋白2抑制剂在日本心力衰竭合并糖尿病患者中的不良事件特征分析(来自日本药物不良反应报告数据库)
Toshiaki Sakamoto,Hirotaka Miyamoto,Junya Hashizume et al.
Toshiaki Sakamoto et al.
Comment on: "Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database." [0.03%]
述评：利用日本药物不良事件报告数据库分析钠-葡萄糖共转运蛋白2抑制剂在糖尿病合并心力衰竭患者中的不同不良事件特点
Yoshihiro Noguchi,Keiko Suzuki,Yoko Ino et al.
Yoshihiro Noguchi et al.
Optimizing Individualized Antimicrobial Dosing in Pediatric Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [0.03%]
基于随机对照试验的儿科个体化抗微生物药物剂量优化的系统评价和 meta 分析
Nadir Yalçın,Yağmur Dirik,İzgi Bayraktar et al.
Nadir Yalçın et al.
Background: Therapeutic drug monitoring (TDM) and target concentration intervention (TCI) represent significant advancements in individualized medicine, aiming to tailor dosages based on patient-specific characteristics. ...
Phenotypes of Patients with Direct Oral Anticoagulant (DOAC) Underdosing in Atrial Fibrillation: Results from the ARENA Registry [0.03%]
来自Arena登记处的房颤直接口服抗凝药（DOAC）减量患者的表型结果
Christine Brockmüller,Andreas D Meid,Jochen Senges et al.
Christine Brockmüller et al.
Background and objectives: Oral anticoagulation in patients with atrial fibrillation is crucial to prevent thrombus formation in the heart, a major cause of ischemic stroke. The appropriate dose of direct oral anticoagula...
Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study [0.03%]
NUN-004（新型工程化Ephrin拮抗剂）在健康志愿者和肌萎缩侧索硬化症患者中的I/Ib期、开放标签、剂量递增及扩展试验：一项关于其疗效的评估研究
Michael Gerometta,Robert D Henderson,Richard Friend et al.
Michael Gerometta et al.
Background: Erythropoietin-producing hepatocellular carcinoma A4 (EphA4) is implicated in the pathophysiology of amyotrophic lateral sclerosis. EphA4 fusion protein (EphA4-Fc) inhibits EphA4 function in vivo but is too sh...
Evaluation of the Effectiveness of Additional Risk Minimisation Measures for Tofacitinib (Xeljanz®) in Europe: A Prescriber Survey [0.03%]
托法替尼(XELJANZ®)欧洲额外风险最小化措施有效性的评价：基于处方医生的问卷调查研究
Joanne Wu,Nana Koram,Kofi Asomaning et al.
Joanne Wu et al.
Objective: We evaluated the effectiveness of tofacitinib (oral Janus kinase inhibitor) additional risk minimisation measures (aRMM) in Europe via prescriber surveys. Operational challenges/methodological limitations of su...
A Network Meta-Analysis of Vasodilator Therapies in Pulmonary Hypertension Patients Undergoing Mitral Valve Replacement Surgery: Insights for Optimizing Hemodynamics [0.03%]
肺动脉高压患者二尖瓣置换术中血管扩张剂治疗的网络 meta 分析：改善血流动力学的启示
Amr Elrosasy,Ahmed Maher,Abdelraouf Ramadan et al.
Amr Elrosasy et al.
Background and objective: Pulmonary hypertension (PH) is a progressive hemodynamic condition associated with significant morbidity and mortality, especially in patients undergoing cardiac surgery. Therefore, the objective...
A Phase I Clinical Trial to Evaluate the Bioequivalence of an Adalimumab Biosimilar Adalimumab-WIBP and Humira® [0.03%]
评价阿达木单抗类似药IBI-303与原研修美谭(阿达木单抗)生物等效性的Ⅰ期临床试验
Shengling Hu,Yang Liu,Lu Yang et al.
Shengling Hu et al.
Background and objectives: The high costs associated with biological agents often limit accessibility for many patients, whereas biosimilars allow the wider application of biological treatment. The objectives of this phas...
A Single-Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Monthly Extended-Release Buprenorphine at Alternative Injection Locations in Adult Participants with Opioid Use Disorder [0.03%]
关于在成人受试者中评估月剂量缓释布施洛芬在不同注射位置的相对生物利用度、安全性和耐受性的单次给药研究
Celine M Laffont,Olga Lapeyra,Dipti Mangal et al.
Celine M Laffont et al.
Background and objectives: Buprenorphine extended-release monthly formulation (BUP-XR, SUBLOCADE®) is approved for treatment of moderate-to-severe opioid use disorder (OUD) following subcutaneous injection in the abdomen...
Randomized Controlled Trial
Clinical drug investigation. 2024 Dec;44(12):939-949. DOI:10.1007/s40261-024-01406-7 2024